UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2015	Jul. 31, 2014
Operating revenue:
Personalized oncology solutions	$ 485	$ 341
Translational oncology solutions	2,337	1,571
Total operating revenue	2,822	1,912
Costs and operating expenses:
Cost of personalized oncology solutions	661	757
Cost of translational oncology solutions	1,612	965
Research and development	1,100	1,423
Sales and marketing	1,029	1,034
General and administrative	1,317	1,462
Total costs and operating expenses	5,719	5,641
Loss from operations	(2,897)	(3,729)
Other (expense) income:
Change in fair value of warrant liability	0	155
Other (expense)/income, net	(10)	31
Total other (expense) income	(10)	186
Loss before provision for income taxes	(2,907)	(3,543)
Provision for income taxes	6	5
Net loss	$ (2,913)	$ (3,548)
Net loss per common share outstanding
basic (in dollars per share)	$ (0.33)	$ (0.64)
diluted (in dollars per share)	$ (0.33)	$ (0.64)
Weighted average common shares outstanding
basic (in shares)	8,702,237	5,573,822
diluted (in shares)	8,702,237	5,819,657